These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 17503740)

  • 21. In Vivo Multidimensional Brain Imaging in Huntington's Disease Animal Models.
    Flament J; Hantraye P; Valette J
    Methods Mol Biol; 2018; 1780():285-301. PubMed ID: 29856025
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tauroursodeoxycholic acid, a bile acid, is neuroprotective in a transgenic animal model of Huntington's disease.
    Keene CD; Rodrigues CM; Eich T; Chhabra MS; Steer CJ; Low WC
    Proc Natl Acad Sci U S A; 2002 Aug; 99(16):10671-6. PubMed ID: 12149470
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Axonopathy in Huntington's disease.
    Li JY; Conforti L
    Exp Neurol; 2013 Aug; 246():62-71. PubMed ID: 22921535
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Mechanisms of neuronal death in Huntington's disease. Second part: therapeutic challenges].
    Bantubungi K; Blum D
    Rev Med Brux; 2007; 28(6):487-94. PubMed ID: 18265808
    [TBL] [Abstract][Full Text] [Related]  

  • 25. AUTEN-67 (Autophagy Enhancer-67) Hampers the Progression of Neurodegenerative Symptoms in a Drosophila model of Huntington's Disease.
    Billes V; Kovács T; Hotzi B; Manzéger A; Tagscherer K; Komlós M; Tarnóci A; Pádár Z; Erdős A; Bjelik A; Legradi A; Gulya K; Gulyás B; Vellai T
    J Huntingtons Dis; 2016 May; 5(2):133-47. PubMed ID: 27163946
    [TBL] [Abstract][Full Text] [Related]  

  • 26. New Avenues for the Treatment of Huntington's Disease.
    Kim A; Lalonde K; Truesdell A; Gomes Welter P; Brocardo PS; Rosenstock TR; Gil-Mohapel J
    Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445070
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sirtuins as Modifiers of Huntington's Disease (HD) Pathology.
    Neo SH; Tang BL
    Prog Mol Biol Transl Sci; 2018; 154():105-145. PubMed ID: 29413175
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Adenosine receptors and Huntington's disease: implications for pathogenesis and therapeutics.
    Blum D; Hourez R; Galas MC; Popoli P; Schiffmann SN
    Lancet Neurol; 2003 Jun; 2(6):366-74. PubMed ID: 12849153
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Protective Effects of Antioxidants in Huntington's Disease: an Extensive Review.
    Essa MM; Moghadas M; Ba-Omar T; Walid Qoronfleh M; Guillemin GJ; Manivasagam T; Justin-Thenmozhi A; Ray B; Bhat A; Chidambaram SB; Fernandes AJ; Song BJ; Akbar M
    Neurotox Res; 2019 Apr; 35(3):739-774. PubMed ID: 30632085
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Neural and mesenchymal stem cells in animal models of Huntington's disease: past experiences and future challenges.
    Kerkis I; Haddad MS; Valverde CW; Glosman S
    Stem Cell Res Ther; 2015 Dec; 6():232. PubMed ID: 26667114
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Huntington's disease.
    Roze E; Bonnet C; Betuing S; Caboche J
    Adv Exp Med Biol; 2010; 685():45-63. PubMed ID: 20687494
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ectopic expression of the striatal-enriched GTPase Rhes elicits cerebellar degeneration and an ataxia phenotype in Huntington's disease.
    Swarnkar S; Chen Y; Pryor WM; Shahani N; Page DT; Subramaniam S
    Neurobiol Dis; 2015 Oct; 82():66-77. PubMed ID: 26048156
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Proteomics of Huntington's disease-affected human embryonic stem cells reveals an evolving pathology involving mitochondrial dysfunction and metabolic disturbances.
    McQuade LR; Balachandran A; Scott HA; Khaira S; Baker MS; Schmidt U
    J Proteome Res; 2014 Dec; 13(12):5648-59. PubMed ID: 25316320
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Weight loss in Huntington disease increases with higher CAG repeat number.
    Aziz NA; van der Burg JM; Landwehrmeyer GB; Brundin P; Stijnen T; ; Roos RA
    Neurology; 2008 Nov; 71(19):1506-13. PubMed ID: 18981372
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Therapeutic effects of stem cells in rodent models of Huntington's disease: Review and electrophysiological findings.
    Holley SM; Kamdjou T; Reidling JC; Fury B; Coleal-Bergum D; Bauer G; Thompson LM; Levine MS; Cepeda C
    CNS Neurosci Ther; 2018 Apr; 24(4):329-342. PubMed ID: 29512295
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Huntington's disease: clinical characteristics, pathogenesis and therapies.
    Nakamura K; Aminoff MJ
    Drugs Today (Barc); 2007 Feb; 43(2):97-116. PubMed ID: 17353947
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The R6 lines of transgenic mice: a model for screening new therapies for Huntington's disease.
    Gil JM; Rego AC
    Brain Res Rev; 2009 Mar; 59(2):410-31. PubMed ID: 19118572
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Recent advances in Huntington's disease: implications for experimental therapeutics.
    Feigin A; Zgaljardic D
    Curr Opin Neurol; 2002 Aug; 15(4):483-9. PubMed ID: 12151847
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical Aspects of Huntington's Disease.
    Ghosh R; Tabrizi SJ
    Curr Top Behav Neurosci; 2015; 22():3-31. PubMed ID: 23975844
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Surveying the landscape of Huntington's disease mechanisms, measurements, and medicines.
    Crook ZR; Housman DE
    J Huntingtons Dis; 2013; 2(4):405-36. PubMed ID: 25062729
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.